(-0.02%) 5 221.42 points
(-0.21%) 39 432 points
(0.29%) 16 388 points
(0.21%) $79.29
(-0.55%) $2.37
(0.08%) $2 344.80
(0.36%) $28.55
(0.14%) $1 012.20
(0.04%) $0.927
(0.04%) $10.81
(0.02%) $0.796
(-0.01%) $91.59
Live Chart Being Loaded With Signals
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas...
Stats | |
---|---|
Today's Volume | 3.08M |
Average Volume | 1.49M |
Market Cap | 1.09B |
EPS | HKD0 ( 2024-03-27 ) |
Next earnings date | ( HKD0 ) 2024-06-06 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.17 |
ATR14 | HKD0.00500 (0.35%) |
Volume Correlation
HBM Holdings Limited Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
HBM Holdings Limited Correlation - Currency/Commodity
HBM Holdings Limited Financials
Annual | 2023 |
Revenue: | HKD89.50M |
Gross Profit: | HKD87.47M (97.73 %) |
EPS: | HKD0.0300 |
FY | 2023 |
Revenue: | HKD89.50M |
Gross Profit: | HKD87.47M (97.73 %) |
EPS: | HKD0.0300 |
FY | 2022 |
Revenue: | HKD40.66M |
Gross Profit: | HKD40.53M (99.68 %) |
EPS: | HKD-0.190 |
FY | 2021 |
Revenue: | HKD4.31M |
Gross Profit: | HKD4.17M (96.82 %) |
EPS: | HKD-0.179 |
Financial Reports:
No articles found.
HBM Holdings Limited
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators